Literature DB >> 3701603

Kinetic models of induction: I. Persistence of the inducing substance.

F P Abramson.   

Abstract

A kinetic model for induction is presented which includes the pharmacokinetics of the inducing agent. When simulations based on this model are carried out, they demonstrate situations where the observed rate constant governing the change from the basal to the induced state, or from the induced to the basal state, differs substantially from the true turnover rate constant. This arises from the confounding influences of the accumulation or persistence of either the inducing agent itself or some intermediary metabolic process. Depending on the relationships between the kinetic constants, there are four experimental subsets which require various interpretative schemes to obtain a correct estimate of the turnover rate constant. These interpretive schemes point out the necessity of measuring the pharmacokinetics of the inducer in all experiments.

Mesh:

Year:  1986        PMID: 3701603     DOI: 10.1002/jps.2600750302

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 3.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

4.  Characterization of the time course of carbamazepine deinduction by an enzyme turnover model.

Authors:  Baralee Punyawudho; James C Cloyd; Ilo E Leppik; R Eugene Ramsay; Susan E Marino; Page B Pennell; James R White; Angela K Birnbaum
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2018-09-12       Impact factor: 4.009

7.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Authors:  A V Boddy; M Cole; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  The effects of phenytoin dosage on the induction of alpha 1-acid glycoprotein and antipyrine clearance in the dog.

Authors:  F P Abramson; M P Lutz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

9.  A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.

Authors:  Beth Apsel Winger; Susie E Long; Jordan Brooks; Ashish O Gupta; Christopher C Dvorak; Janel Renee Long-Boyle
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.